Dysfunction of phospholipase Cγ in immune disorders and cancer

Trends Biochem Sci. 2014 Dec;39(12):603-11. doi: 10.1016/j.tibs.2014.09.004.

Hans Koss ¹, Tom D Bunney ², Sam Behjati ³, Matilda Katan ⁴

Affiliations

1 Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK; Division of Molecular Structure, Medical Research Council (MRC) National Institute for Medical Research, London, UK.
2 Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK. Electronic address: [email protected].
3 Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
4 Institute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK. Electronic address: [email protected].

PMID: 25456276 DOI: 10.1016/j.tibs.2014.09.004

Abstract

The surge in genetic and genomic investigations over the past 5 years has resulted in many discoveries of causative variants relevant to disease pathophysiology. Although Phospholipase C (PLC) Enzymes have long been recognized as important components in intracellular signal transmission, it is only recently that this approach highlighted their role in disease development through gain-of-function mutations. In this review we describe the new findings that link the PLCγ family to immune disorders and Cancer, and illustrate further efforts to elucidate the molecular mechanisms that underpin their dysfunction.

Keywords

cancer; deregulation of signaling; disease-linked mutations; immune disorders; phospholipase C.

Name
Email *

	Sorry, but the email address you supplied was invalid.